PMID- 25143188
OWN - NLM
STAT- MEDLINE
DCOM- 20160309
LR  - 20221207
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 31
IP  - 8
DP  - 2014 Aug
TI  - Lixisenatide treatment for older patients with type 2 diabetes mellitus 
      uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled 
      trials.
PG  - 861-72
LID - 10.1007/s12325-014-0146-4 [doi]
AB  - AIM: Evaluate the efficacy and safety of lixisenatide, a once-daily prandial 
      glucagon-like peptide-1 receptor agonist, in older patients with type 2 diabetes 
      mellitus (T2DM) insufficiently controlled on oral antidiabetics (OADs). METHODS: 
      A meta-analysis was conducted on data from older patients (>/=65 years) from five 
      of the GetGoal trials, in which patients with T2DM were treated with lixisenatide 
      20 microg once daily or placebo, as an add-on to OADs. The primary endpoint in all 
      trials was change from baseline at week 24 in glycated hemoglobin (HbA1c). Other 
      endpoints included changes in post-prandial plasma glucose (PPG), fasting plasma 
      glucose (FPG) and weight. Composite and safety endpoints were also analyzed. 
      RESULTS: A total of 501 patients aged >/=65 years were included in this 
      meta-analysis: 304 received lixisenatide plus OADs and 197 received placebo as 
      add-on to OADs. Lixisenatide as an add-on to OADs significantly reduced HbA1c, 
      PPG, FPG and weight, with placebo-corrected treatment effects at week 24 of 
      -0.54% (p<0.0001), -126 mg/dL (p<0.0001), -13 mg/dL (p=0.0005) and -0.90 kg 
      (p=0.0021), respectively. Patients receiving lixisenatide plus OADs were 
      significantly more likely to achieve composite (HbA1c levels<7%, HbA1c levels<7% 
      and no symptomatic hypoglycemia, and HbA1c levels<7%, no weight gain and no 
      symptomatic hypoglycemia) and safety endpoints than those receiving placebo plus 
      OADs. Symptomatic hypoglycemia was experienced by 8.55% and 3.55% of patients in 
      the lixisenatide plus OADs and placebo plus OADs groups, respectively (p=0.0276), 
      although no serious hypoglycemic episodes were reported. CONCLUSIONS: 
      Lixisenatide plus OADs improved glycemic control in older patients inadequately 
      controlled on OADs compared with placebo plus OADs. Lixisenatide is well tailored 
      to the pathophysiology of T2DM in older patients.
FAU - Hanefeld, Markolf
AU  - Hanefeld M
AD  - GWT-TUD, Study Centre Prof. Hanefeld, Dresden Technical University, Fiedlerstr. 
      34, 01307, Dresden, Germany, hanefeld@gwtonline-zks.de.
FAU - Berria, Rachele
AU  - Berria R
FAU - Lin, Jay
AU  - Lin J
FAU - Aronson, Ronnie
AU  - Aronson R
FAU - Darmon, Patrice
AU  - Darmon P
FAU - Evans, Marc
AU  - Evans M
FAU - Van Gaal, Luc
AU  - Van Gaal L
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20140821
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 74O62BB01U (lixisenatide)
MH  - Aged
MH  - Blood Glucose
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Peptides/administration & dosage/adverse effects/*therapeutic use
MH  - Postprandial Period
MH  - Randomized Controlled Trials as Topic
EDAT- 2014/08/22 06:00
MHDA- 2016/03/10 06:00
CRDT- 2014/08/22 06:00
PHST- 2014/06/05 00:00 [received]
PHST- 2014/08/22 06:00 [entrez]
PHST- 2014/08/22 06:00 [pubmed]
PHST- 2016/03/10 06:00 [medline]
AID - 10.1007/s12325-014-0146-4 [doi]
PST - ppublish
SO  - Adv Ther. 2014 Aug;31(8):861-72. doi: 10.1007/s12325-014-0146-4. Epub 2014 Aug 
      21.